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Abstract
The fundamental goal of generative drug design is to propose optimized molecules
that meet predefined activity, selectivity, and pharmacokinetic criteria. Despite
recent progress, we argue that existing generative methods are limited in their
ability to favourably shift the distributions of molecular properties during opti-
mization. We instead propose a novel Reinforcement Learning framework for
molecular design in which an agent learns to directly optimize through a space of
synthetically-accessible drug-like molecules. This becomes possible by defining
transitions in our Markov Decision Process as chemical reactions, and allows
us to leverage synthetic routes as an inductive bias. We validate our method by
demonstrating that it outperforms existing state-of the art approaches in the opti-
mization of pharmacologically-relevant objectives, while results on multi-objective
optimization tasks suggest increased scalability to realistic pharmaceutical design
problems.
1 Introduction
Following advances in generative modelling for domains such as computer vision and natural
language processing, there has been increased interest in applying generative methods to drug
discovery. However, such approaches often fail to address numerous technical challenges inherent
to molecular design, including accurate molecular reconstruction, efficient exploration of chemical
space, and synthetic tractability of generated molecules. Further, these approaches bias the generation
of molecules towards the data distribution over which they were trained, restricting their ability
to discover truly novel compounds. Previous work [35, 36] has attempted to address these issues
by framing molecular design as a reinforcement learning problem [28], in which an agent learns
a mapping from a given molecular state to atoms that can be added to the molecule in a step-wise
manner. These approaches generally ensure validity of the generated compounds and avoid the need
to learn a latent space mapping from the data. However, they do not address the issue of synthetic
tractability, and the proposed atom-by-atom environment transitions prevent rapid exploration of
chemical space.
We instead approach the problem in a way that incorporates a favourable bias into the Markov Decision
Process. Specifically, we define the environment’s state transitions as sequences of chemical reactions,
allowing us to address the common issue of synthetic accessibility. While ensuring synthezability
of computationally-generated ligands is challenging, our framework treats synthesizability as a
feature rather than as a constraint. Our approach, deemed REACTOR (REACTion-driven Objective
Reinforcement), thus addresses a common limitation of existing methods, whereby the synthetic routes
for generated molecules are unknown and require challenging retro-synthetic planning. Importantly,
the REACTOR framework is able to efficiently explore synthetically-accessible chemical space in a
goal-directed manner, while also providing a theoretically-valid synthetic route for each generated
compound.
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We benchmark our approach against previous methods, focusing on the task of identifying novel
ligands for the D2 dopamine receptor (DRD2), a G protein-coupled receptor involved in a wide range
of neuropsychiatric and neurodegenerative disorders [23]. In doing so, we find that our approach
outperforms previous state-of-the-art methods, is robust to the addition of multiple optimization
criteria, and produces synthetically-accessible, drug-like molecules by design.
2 Related Work
Computational drug design has traditionally relied on domain knowledge and heuristic algorithms.
Recently, however, several machine learning based generative approaches have also been proposed.
Many of these methods, such as [14], take advantage of the SMILES representation using Recurrent
Neural Networks (RNNs) but have difficulties generating syntactically valid SMILES. Graph-based
approaches [8, 15, 20] have also been proposed and generally result in improved chemical validity.
These methods learn a mapping from molecular graphs to a high-dimensional latent space from which
molecules can be sampled and optimised. In contrast, pure reinforcement learning algorithms such as
[35, 36] treat molecular generation as a Markov Decision Process, in which molecules are assembled
from basic building blocks such as atoms and fragments. However, a core limitation of existing
methods is the forward-synthetic feasibility of proposed designs. To overcome these limitations,
[7] propose a hybrid rule-based and machine learning approach in which molecules are assembled
from fragments under synthetic accessibility constraints in an iterative single-step process. However,
this approach is limited in terms of the flexibility of its optimisation objectives, as it only allows for
generation of molecules similar to a given template ligand.
In order to have practical value, methods for computational drug design must also make appropriate
tradeoffs between molecular generation, which focuses on the construction of novel and valid
molecules, and molecular optimization, which focuses on the properties of the generated compounds.
While prior work has attempted to address these challenges simultaneously, this can lead to sub-
optimal results by favouring either the generation or the optimization tasks. Generative models
generally do not scale well to complex property optimization problems, as they attempt to bias the
generation process towards a given objective within the latent space while simultaneously optimizing
over the reconstruction loss. These objectives are often conflicting, making goal-directed optimization
difficult and hard to scale when multiple reward signals are required. This is generally the case in
drug design, where drug candidates must show activity against a given target as well as favourable
selectivity, toxicity, and pharmacokinetic properties.
In contrast, atom-based reinforcement learning addresses the generative problem via combinatorial
enumeration of molecular states [36] or a posteriori verification of molecules[35]. These solutions
are often slow, and create a bottleneck in the environment’s state transitions that limits effective
optimization.
3 Methodology
In this work, we decompose generation and optimization by delegating each problem to a distinct
component of our computational framework. Specifically, we allow an Environment module to
handle the generative process, using known chemistry as a starting point for its design, while an
Agent learns to effectively optimize compounds through interactions with this Environment. By
disambiguating the responsibilities of each component, and by formalizing the problem as a Markov
Decision Processes (MDPs), we allow the modules to work symbiotically, exploring chemical space
both more efficiently and more effectively.
We begin with a short overview of Markov Decision Processes and Actor-Critic methods for rein-
forcement learning before defining our framework in detail.
3.1 Background
3.1.1 Markov Decision Processes
A Markov Decision Process (MDP) [4] is a powerful computational framework for sequential
decision-making problems. An MDP is defined via the tuple (S,A,R,P), where S defines the
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possible states, A denotes the possible actions that may be taken at any given time, R denotes the
reward distribution of the environment, and P defines the dynamics of the environment. Interactions
within this framework give rise to trajectories of the form (s0, a0, r1, s1, a1, ...., rT , sT ), with T a
terminal time step. Crucially, an MDP assumes that:
p(st+1, rt+1|at, st, rt, ..., a0, s0) = p(st+1, rt+1|at, st) (1)
where t denotes discrete time steps.
This definition states that all prior history of a decision trajectory can be encapsulated within the
preceding state, allowing an agent operating within an MDP to make decisions based solely on the
current state of the environment. This assumption provides the basis for efficient learning, and holds
under our proposed framework. An agent’s mapping from any given state to action probabilities is
termed a policy, and the probability of an action a ∈ A at state s is denoted pi(a|s).
3.1.2 Policy Optimization
The underlying objective of a Reinforcement Learning agent operating in an MDP is to optimize its
policy to maximize the expected return from the environment, until termination at time T , defined for
any step t by:
Epi[Gt] = Epi[
T∑
m=t+1
γm−t−1rm] (2)
where γ is a discount factor determining the value of future rewards, and the expectation is taken over
the experience induced by the policy’s distribution. Several approaches exist for learning a policy
that maximizes this quantity. In value-based approaches, Q-values of the form Q : SXA −→ R are
trained to estimate the scalar value of action-value pairs as estimates of the expected return. A policy
is then derived from these values through strategies such as -greedy control [28]. Alternatively,
policy-based approaches attempt to parameterize the agent’s behaviour directly, for example through
a neural network, to produce piθ(a|s). While our framework is agnostic to the specific algorithm used
for learning, we choose to validate our approach with an actor-critic architecture [17]. This approach
combines the benefits of learning a policy directly using a policy network piθ, with a variance-reducing
value network vθ′ . Specifically, we use a synchronous version of [21], which is amenable to high
parallelization and further gains in training efficiency. The Advantage Actor-Critic (A2C) objective
function at time t is given by
L(θ, θ′) = log(piθ(at|st))
k∑
i=0
(rt+i + γ
ivθ′(st+i)− vθ′(s)) + βH(piθ(st) (3)
= log(piθ(at|st))At(st, at, θ′, k) + βH(piθ(st)) (4)
Intuitively, maximization of equation 4’s first term involves adjusting the policy parameters to align
high probability of an action with high expected return, while the second term serves as an entropy
regularizer preventing the policy from converging too quickly to sub-optimal deterministic policies.
3.2 Molecular Design via Synthesis Trajectories
A core insight of our framework is that we can embed knowledge about the dynamics of chemical
transitions into a Reinforcement Learning system for guided exploration. In doing so, we induce
a bias over the optimization task which, given its close correspondence with natural molecular
transitions, should increase learning efficiency while leading to better performance across a larger,
pharmacologically relevant chemical subspace.
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We propose embedding this bias into the transition model of an MDP by defining possible transitions
as true chemical reactions. This allows us to gain the additional benefit of built-in synthetic accessibil-
ity, in addition to immediate access to one possible synthesis route for generated compounds. This is
demonstrated in Figure 1, where a sample trajectory is provided by REACTOR for a DRD2-optimized
molecule, while a high-level overview of our framework is presented in Figure 2.
Br
NH
(2)
+(1)
NH
O
S
O
OH
H2N
NH
O
S
O
HO
OH
S
(3) NHBr+H2N
NH
O
S
H2N
O
N
NH
S
NH
O
S
O
OH
Isocyanates hydrolysis
(Curtius rearrangement)
Williamson ether synthesis
Amines alkylation 
using alkyl halides
DRD2 : 1
DRD2 : 0
Figure 1: A trajectory taken by the REACTOR agent during the optimization of affinity for the
Dopamine receptor D2. This trajectory provides a high-level overview of a possible synthesis route
for the proposed molecule. We note however that although the proposed route is theoretically feasible,
it would not be the first choice for synthesis and can easily be optimized. Nevertheless, it remains an
important indication of synthesizability. We also note here that the agent learns a policy that produces
structures containing a piperidine moiety, which have been shown as actives against dopamine
receptors [13].
3.2.1 Framework Definition
We define each component of our MDP as follows:
State Space S
We allow for any valid molecule to comprise a state in our MDP. Practically, the state space is
defined as {f(m)|m ∈ M}, with f a feature extraction function, M the space of molecules
reachable given a set of chemical reactions, initialization molecules, and available reactants. We use
Morgan Fingerprints [25] with bit-length 2048 and radius 2 to extract feature vectors from molecules.
These representations have been shown to provide robust and efficient featurizations, while more
computationally-intensive approaches like Graph Neural Networks are yet to demonstrate significant
representational benefit [16, 33].
Action Space A
In its general formulation, the action space of our framework is defined hierarchically, enabling the
potential application of novel approaches for hierarchical reinforcement learning. Specifically, we
define a set of higher-level actions Ao as a curated list of chemical reaction templates, taking the
form:
R := r1 + r2 + ...+ rk → (p1, ..., pm) (5)
Each ri corresponds to a reactant, while each pj is a product of this reaction. We make use of the
SMARTS syntax [1] to represent these objects as regular expressions. At step t, the state st thus
corresponds to a single reactant in any given reaction. It is necessary to select which molecular blocks
should fill in the remaining pieces for a given state and reaction selection. This gives rise to a set of
primitive actionsAi corresponding to a list of reactants derived from the reaction templates, which we
also refer to as chemical building blocks. In contrast with previous methods [35, 36], which establish
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Figure 2: Overview of the REACTOR framework. Each episode is initialized with a molecular
building block. At each step, the current state is converted to its fingerprint representation, and the
policy model selects a reaction to be performed. A reactant selection heuristic completes the reaction
to generate the next state in the episode, while a reward of 0 is returned. Instead, if the terminal action
is selected, the current state is considered as the final molecule and its reward is used to update the
policy’s parameters.
a deterministic start state such as an empty molecule or carbon atom, we initialize our environment
with a randomly-sampled building block which matches at minimum one reaction template. This
ensures that a trajectory can take place and encourages the learned policies to be generalizable across
different regions in chemical space.
For our experiments, we work with two-reactant reaction templates and select missing reactants
based on those which will most improve the next state’s reward. We also select the chemical product
in this manner when more than one product is generated. Doing so collapses our hierarchical
formulation into a standard MDP formulation, with the reaction selection being the only decision
point. Additionally, it is likely that for any step t, the set of possible reactions is smaller than the
full action space. In order to increase both the scalability of our framework (by allowing for larger
reaction lists) and the speed of training, we use a mask over unfeasible reactions. This avoids the need
for the agent to learn the chemistry of reaction feasibility, and reduces the effective dimension of the
action space at each step. The policy then takes the form pi(at|st,M(st)), with M the environment’s
masking function. We discuss potential mechanisms to make use of the hierarchical formulation of
the action space in Section 5.
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Reward DistributionR
Appropriate reward design is crucial given that it drives the policy optimization process. In [35],
intermediate and adversarial rewards are introduced in order to enforce drug-likeness and validity of
generated compounds. In [36], these requirements are ignored, and while optimization performance
increases, desirable pharmaceutical properties are often lost. In the REACTOR framework, the
separation between the agent and the environment allows us to maintain property-focused rewards
that guide optimization while ensuring chemical constraints are met via environment design.
We use a deterministic reward function based on the property to be optimized. In 1, this corresponds
to the binary prediction of compounds binding to the D2 Dopamine Receptor (DRD2). In 3, these
are the penalized calculated octanol-water partition coefficient (cLogP) and quantitative estimate
of drug-likeness (QED) [5]. In order to avoid artificially biasing our agent towards greedy policies,
we remove intermediate rewards and provide evaluative feedback only at termination of an episode.
While we feel this is a more principled view on the design process, [36] have also suggested that
using an intermediate reward discounted by a decreasing function of the step t may improve learning
efficiency. In 1, we further apply a constraint based on the atom count of a molecule to be consistent
with prior work. When molecules exceed the maximum number of heavy atoms (38), the agent
observes a reward of zero.
Transition Model P
In the template-based REACTOR framework, state transitions are deterministic. We therefore have
p(st+1|st, at) = 1, according to our choice of reaction and the subsequent reactant-product selection.
When modifying the reactant-selection policy, either via a stochastic heuristic such as an epsilon-
greedy reactant selection, or learned hierarchical policies, state transitions over the higher level
actions Ao become stochastic according to the internal policy’s dynamics.
4 Experiments
To validate our framework, we benchmark its performance on goal-directed design tasks, focusing
primarily on predicted activity for the D2 Dopamine Receptor. To maintain consistency with
experiments done in prior work, we also perform additional experiments on penalized cLogP and
QED, with the results presented in Supplementary Material.
In order to better understand the exploration behaviour of our approach, we also investigate the nature
of the trajectories generated by the REACTOR policies, showing that policies retain drug-likeness
across all optimization objectives, while also exploring distinct regions of chemical space.
4.1 Experimental Setup
Baselines We compare our approach to two recent methods in deep generative molecular modelling,
JT-VAE and ORGAN [14, 15]. Each of these approaches was first pre-trained for up to 48h on
the same compute facility, a single machine with 1 NVIDIA Tesla K80 GPU and 16 CPU cores.
Property optimization was then performed using the same procedures as described in the original
papers. We also compare our method with two state-of-the-art reinforcement learning approaches,
Graph-Convolutional Policy Networks and MolDQN [35, 36]. Each algorithm was run using the
open-sourced code from the authors, while we enforced the same reward function implementation
across methods to ensure consistency. We ran GCPN using 32 CPU cores for approximately 24 hours
(against 8 hours in the original paper), and MolDQN for 20000 episodes (against 5000 episodes in the
original paper). In addition, we added a steepest-ascent hill-climbing baseline using the REACTOR
environment to demonstrate that for simple, mostly greedy objectives such as cLogP and QED, simple
search policies may provide reasonable performance. In contrast, learned traversals of space become
necessary for complex tasks such as DRD2.
Evaluation Given the inherent differences between generative and reinforcement learning models,
evaluation was adapted to remain consistent within each class of algorithms. JT-VAE and ORGAN
were evaluated based on decoded samples from their latent space, using the best results across training
checkpoints, with statistics for JT-VAE computed over 3 random seeds. Given the prohibitive cost of
training ORGAN, results are given over a single seed. Other baselines were compared based on three
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sets of 100 building blocks used as starting states. Statistics are reported over sets, while the statistics
of the initial states are shown by BLOCKS.
We prioritize evaluation of each method based on mean reward, given that this corresponds to the
underlying optimization objectives for reinforcement learning methods. This is denoted by Activity
in Table 1, which corresponds to the percentage of generated molecules which are predicted active
for the DRD2 receptor. In both Table 1 and Table 3, mean reward was computed based on the set
of unique molecules generated by each algorithm, in order to avoid artificially favouring methods
which often generate the same molecule. Diversity corresponds to the average pairwise Tanimoto
distance among generated molecules, while "Scaff. Similarity" corresponds to the average pairwise
similarity between the scaffolds of the compounds, as implemented by [24]. Finally, we limited the
number of atoms to 38 for all single-objective tasks, as done in prior work [15, 35, 36], and to 50 for
the multi-objective tasks.
4.2 Goal-Directed De Novo Design
Table 1: Goal-Directed Molecule Design.
Objective Method Activity Diversity Scaff. Similarity Uniqueness
DRD2 BLOCKS 3% ± 0 0.94 ± 0 N/A 100% ± 0
Hill Climbing 62% ± 0 0.91 ± 0 0.15 ± 0.01 100% ± 0
ORGAN 1% 0.89 0.172 77.1%
JTVAE 11% ± 16% 0.06 ± 0.08 N/A 3% ± 2%
GCPN 5% ± 2% 0.92 ± 0 0.13 ± 0 100% ± 0
MolDQN 89% ± 2% 0.88 ± 0 N/A 97% ± 1.8%
REACTOR 98% ± 1% 0.71 ± 0.01 0.22 ± 0.02 99.7% ± 0.5%
Computation of Scaffold Similarity requires the presence of a ring system, thus the N/A.
Results on the unconstrained design task show that REACTOR achieves highest mean reward for
the DRD2 objective. We also observe that REACTOR maintains high diversity and uniqueness in
addition to robust performance. This a crucial characteristic, as it implies that the agent is able to
optimize the space surrounding each starting molecule, without reverting to the same molecule to
optimize the scalar reward signal. In Table 3, REACTOR also achieves higher reward on QED, while
remaining competitive on penalized cLogP despite the simplistic nature of this objective favouring
atom-by-atom transitions.
Training efficiency is an important practical consideration while deploying methods for de novo
design. Generative models first require learning a mapping of molecules to the latent space before
training for property optimization. During our experiments, this resulted in more than 48h of training
time. Reinforcement learning methods trained faster, but generally failed to converge within 24
hours. In contrast, as shown in Figure 8 (Supplementary Material), our approach converges within
approximately two hours of training.
4.3 Synthetic Tractability and Desirability of Optimized Compounds
Given the narrow perspective offered by quantitative benchmarks for molecular design models [24],
it is equally important to qualitatively assess the behaviour of these models by examining generated
compounds. Figure 4 provides samples generated by each RL method across all objectives. Since
the computational estimation of cLogP relies on the Wildman-Crippen method [32], which assigns a
high atomic contribution to Halogens and Phosphorous, the atom-based action space of MolDQN
produces samples that are heavily biased towards these atoms, resulting in molecules that are well
optimized for the task but neither synthetically-accessible nor drug-like. This generation bias was
not observable in previously reported benchmarks where atom types were only limited to Carbon,
Oxygen, Nitrogen, Sulfur and Halogens [36]. Furthermore, MolDQN samples for the DRD2 task
lack a ring system, and whereas molecules from GCPN have one, none adequately optimize for the
objective.
In contrast, REACTOR appears to produce more pharmacologically desirable compounds, without
explicitly considering this as an optimization objective. This is supported by Figure 3, which shows
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that REACTOR is the only approach able to simultaneously solve the DRD2 task while maintaining
favourable distributions for synthetic-accessibility [9] and drug-likeness.
REACTOR MolDQN GCPN BLOCKS
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
Synthetic Accessibility Score of DRD2-optimized Molecules
REACTOR MolDQN GCPN BLOCKS
0.0
0.2
0.4
0.6
0.8
Drug-Likeness of DRD2-optimized Molecules
Figure 3: Synthetic accessibility and drug-likeness score distributions of molecules optimized for
DRD2 and for the starting blocks.
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Figure 4: Sample molecules produced for each objective by each RL algorithm
Further, as shown in Figure 1 and Figure 7, optimized compounds are provided along with a possible
route of synthesis. While such trajectories may not be optimal, given that they are limited by the
reward design, the set of reaction templates used, their specificity, as well as the availability and cost
of reactants, they provide a crucial indication of synthesizability. In [11], the authors detail the lack
of consideration for synthetic tractability in current molecular optimization approaches, highlighting
that this is a necessary requirement for application of these methods in drug discovery. While
alternate ideas aiming to embed synthesizability constraints into generative models have recently been
explored [6, 7, 18], REACTOR is the first approach which explicitly addresses synthetic feasibility
by optimizing directly in the space of synthesizable compounds using reinforcement learning.
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4.4 Multi-Objective Optimization
Practical methods for computational drug design must be robust to the optimization of multiple
properties. Indeed, beyond the agonistic or antagonistic effects of a small molecule, properties such as
the selectivity, solubility, drug-likeness and permeability of a drug candidate must be considered. To
validate the REACTOR framework under this setting, we consider the task of optimizing for selective
DRD2 ligands. Dopamine receptors are grouped into two classes: D1-like receptors (DRD1, DRD5)
and D2-like receptors (DRD2, DRD3 and DRD4). Although these receptors are well studied, design
of drugs selective across subtypes remains a considerable challenge. In particular, as DRD1 and
DRD3 share 78% structural similarity in their transmembrane region [23, 27], it is very challenging
to identify small molecules that can selectively bind to and modulate their activity. We therefore
assess performance both on selectivity across classes (using DRD1 as off-target) and within classes
(using DRD3 as off-target). We then analyze how our framework performs as we increase the number
of design objectives. For these experiments, we focus our comparison on MolDQN, as it strongly
outperforms other methods on the single-objective tasks. We increase its training to 25,000 episodes
and use reward scalarization to combine multiple objectives. Formally, a vector of reward signals is
aggregated via a mapping S : R1 × ...×Rk → R, thus collapsing the multi-objective MDP [31] into
a standard MDP formulation. While the simplest and most common approach to scalarization is to
use a weighted sum of the individual reward signals, we adopt a Chebyshev scalarization scheme
[30], whereby reward signals are aggregated via the weighted Chebyshev metric:
r = max
i
wi(|ri − z∗i |) (6)
where ~z∗ is a utopian vector, ~w assigns the relative preferences for each objective, and i indexes the
objectives. For our experiments, we consider binary rewards, such that the utopian point is always ~1,
rendering the dynamics of each reward signal more similar, and assign uniform preferences to the
objectives. While Chebyshev scalarization was introduced for tabular Reinforcement Learning, we
can interpret it in the function of approximation setting as defining an adaptive curriculum, whereby
the optimization focus shifts dynamically according to the objective most distant from ~z∗. In Figure
9, we see that this approach for combining reward signals is significantly more robust as the number
of objectives increases.
4.4.1 DRD2 Selectivity
Table 2: DRD2 Selectivity
Objective Method Reward Diversity Scaff. Similarity Uniqueness
D2/D1 MolDQN 0.91 ± 0.02 0.83 ± 0 N/A 99% ± 1%
REACTOR 0.92 ± 0.02 0.52 ± 0.03 0.19 ± 0 100% ± 0
D2/D3 MolDQN 0.92 ± 0.02 0.88 ± 0.01 N/A 100% ± 0
REACTOR 0.97 ± 0.02 0.6 ± 0.02 0.23 ± 0.02 100% ± 0
Rewards in Table 2 and Figure 5 are computed as the proportion of evaluation episodes for which
the algorithms optimize all desired objectives. In Table 2, we find that REACTOR maintains strong
performance on the selectivity tasks, optimizing for DRD2 while avoiding off-target activity on the
D1 and D3 receptors. Further, it is able to outperform MolDQN while maintaining very low scaffold
similarity among generated molecules.
4.4.2 Robustness to Multiple Objectives
In addition to off-target selectivity, we assess the robustness of each method’s performance as we
increase the number of pharmacologically-relevant property objectives to optimize. Specifically, we
compare the following combinations of rewards:
• DRD2 with range-targeted cLogP (2 objectives) according to the Ghose filter [12]
• DRD2, range cLogP, and a molecular weight ranging from 180 to 600 (3 objectives)
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• DRD2, range cLogP, target molecular weight, and drug absorption, as indicated by a model
trained on data for the Caco-2 permeability assay [29] (4 objectives)
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Figure 5: Reward progression as the number of optimization objectives increases.
Figure 5 shows that REACTOR demonstrates greater robustness to an increasing number of design
objectives. Specifically, it maintains a global success rate of approximately 88% when optimizing
for the 4 objective task. Success against DRD2 activity drops more sharply for MolDQN, while the
uniqueness of generated molecules drops to below 20% for 3 and 4 objectives.
4.5 Goal-Directed Exploration
In order to gain further insight into the nature of the trajectories generated by the REACTOR agent,
we plotted two alternative views of optimization routes generated for the same building block across
each single-property objective. In Figure 6, we fit a Principal Components Analysis (PCA) [10] on
the space of building blocks to identify the location of the initial state, and subsequently transform
the next states generated by the RL agent onto this space. We find that the initial molecule is clearly
shifted to distinct regions in space, while the magnitude of the transitions suggest efficient traversal
of the space. This provides further evidence that exploration through space is a function of reward
design, and is mostly unbiased by the data distribution of initialization states. Figure 7 shows the
same trajectories with their corresponding reactions and intermediate molecular states. We find that
optimized molecules generally contain the starting structure. We believe this to be a desirable property
given that real-life design cycles are often focused on a fixed scaffold or set of core structures. We
also note that the policy learned by our REACTOR framework is able to generalize over different
starting blocks, suggesting that it achieves generation of structurally diverse and novel compounds.
(a) Trajectory Initialization (b) Episode Termination
Figure 6: Trajectory steps of the REACTOR agent for each objective, starting with the same building
block. The RL agent shifts the molecule towards different regions in space to identify the relevant
local maximum.
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Figure 7: Trajectories taken by the REACTOR agent from the same building block for different
objectives. Note that the reaction steps are simplified and are mainly indicative of synthesizability. For
example, the Negishi coupling reaction would first require the formation of an organozinc precursor.
Furthermore, selectivity is low at some steps, which will result in a mixture of products, unless
reacting groups are protected.
5 Conclusion
This work proposes a novel approach to molecular design which defines state transitions as chemical
reactions within a reinforcement learning framework. We demonstrate that our framework leads to
globally improved performance, as measured by reward and diversity of generated molecules, as well
as greater training efficiency while producing more drug-like molecules. Analysis of REACTOR’s
robustness to multiple optimization criteria, coupled with its ability to maintain predicted activity
on the DRD2 receptor, suggests increased potential for successful application in drug discovery.
Furthermore, molecules generated by this framework exhibit better synthetic accessibility by design,
with one viable synthesis route also suggested. Although, the reactivity and the stability of the
optimized molecules remain a potential issue, REACTOR’s efficiency in a multiple optimization
setting suggest their explicit consideration as additional design objectives would resolve that issue.
Future work aims to build on this framework by making use of its hierarchical formulation to guide
agent policies both at the higher reaction and lower reactant levels, exploring proposals from [3, 19]
as a starting point. We also plan to expand the effective state space of our MDP by embedding a
more efficient synthesis model, leveraging insights from [26], as the MDP transition model. Because
practical de novo design requires optimization of multiple criteria simultaneously, we believe the
efficiency of our design framework provides a robust foundation for such tasks, and hope to expand
on approaches proposed in [2, 22, 34]. Finally, we intend to validate the bio-activity of generated
molecules experimentally to better demonstrate real-world utility.
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6 Supplementary Material
A Results
Table 3: Goal-Directed Molecule Design
Objective Method Mean Reward Max Reward Diversity Scaff. Similarity Uniqueness
cLogP BLOCKS -1.80 ± 0.08 1.80 ± 0.32 0.94 ± 0 N/A 100% ± 0
Hill Climbing 7.14 ± 0.20 10.90 ± 0.04 0.73 ± 0.01 0.13 ± 0.01 100% ± 0
ORGAN -2.47 0.97 0.83 0.14 63%
JTVAE -1.48 ± 0.56 0.16 ± 0.14 0.54 ± 0.2 N/A 41% ± 34%
GCPN 1.03 ± 0.28 8.51 ± 0.35 0.90 ± 0 0.20 ± 0.01 100% ± 0
MolDQN 12.84 ± 0.23 18.42 ± 0.37 0.71 ± 0.01 0.72 ± 0.23 72% ± 3.6%
REACTOR 8.01 ± 0.18 10.74 ± 0.28 0.69 ± 0.01 0.20 ± 0 99.7% ± 0.5%
QED BLOCKS 0.523 ± 0.005 0.763 ± 0.009 0.94 ± 0 N/A 100% ± 0
Hill Climbing 0.811 ± 0.007 0.943 ± 0.004 0.879 ± 0.003 0.20 ± 0.023 100% ± 0
ORGAN 0.608 0.906 0.871 0.178 89.5%
JTVAE 0.604 ± 0.017 0.876 ± 0.048 0.841 ± 0.018 0.638 ± 0.046 92.8% ± 5.5%
GCPN 0.607 ± 0.012 0.916 ± 0.012 0.91 ± 0.002 0.112 ± 0.004 100% ± 0
MolDQN 0.857 ± 0.026 0.936 ± 0.004 0.791 ± 0.007 0.620 ± 0.123 67% ± 5.8%
REACTOR 0.876 ± 0.007 0.947 ± 0.001 0.878 ± 0.002 0.161 ± 0.021 100% ± 0
B Figures
Reactions 
Training Stopped
Figure 8: Training time for each RL method on each optimization task. REACTOR (labelled
Reactions in the above figure) generally converges within two hours of training, while training is
stopped entirely after 6 hours. We ran MolDQN for 20000 episodes, taking approximately 24 hours,
while GCPN was stopped after 24 hours on 32 CPU cores.
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Figure 9: Comparison of performance across experiments and methods for multi-objective optimiza-
tion when using Chebyshev and Linear Scalarization approaches
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